

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**中國奧園集團股份有限公司**  
**China Aoyuan Group Limited**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 3883)**

**INSIDE INFORMATION**

This announcement is made by China Aoyuan Group Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated 30 June 2022 in relation to, among others, the resumption guidance issued by the Stock Exchange (the “**Resumption Guidance**”) and the fund flows matters of and allegations against subsidiary of the Company and (ii) the announcement of the Company dated 30 September 2022 in relation to quarterly update on resumption progress (collectively, the “**Announcements**”). Terms used in this announcement shall have the same respective meanings as those defined in the Announcements unless otherwise stated.

On 3 October 2022, the investigation firm engaged by the AH’s Investigation Committee (the “**Investigation Firm**”) issued two investigation reports respectively in relation to the first two issues of the Fund Flows Matters as stated in the letter from the AH’s Former Auditor dated 25 March 2022 and the Allegations (collectively, the “**Investigation Reports**”). The Investigation Reports set out, among other things, the key findings of the Investigation Firm in respect of the relevant Fund Flows Matters and the Allegations, details of which are disclosed in the announcement of Aoyuan Healthy dated 3 October 2022.

As at the date of this announcement, the Board is still reviewing and assessing the key findings. The Board will make further announcement in due course to inform the Shareholders and potential investors of the Company if further work will be conducted.

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Friday, 1 April 2022 and will continue to be suspended until, among other things, the Company meets all the Resumption Guidance.

**Shareholders, holders of securities of the Company and other investors of the Company are advised not to rely solely on the information contained in this announcement and are reminded to consider the related risks and exercise caution when dealing in the shares and other securities of the Company.**

By order of the Board  
**China Aoyuan Group Limited**  
**Guo Zi Wen**  
*Chairman*

Hong Kong, 4 October 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Guo Zi Wen, Mr. Guo Zi Ning, Mr. Ma Jun and Mr. Chen Zhi Bin; and the independent non-executive directors of the Company are Mr. Tsui King Fai, Mr. Cheung Kwok Keung and Mr. Lee Thomas Kang Bor.*